Abstract
Importance Olfactory dysfunction is a frequent sequel of SARS-CoV-2 infection. Despite its prevalence, the SARS-CoV-2-related pathophysiology of olfactory dysfunction remains not well understood.
Objective Determine whether long-term olfactory dysfunction in mild to moderate SARS-CoV-2 infection corresponds with structural alteration of the olfactory bulb.
Design, Setting and Participants Data of non-vaccinated COVID-19 convalescents recruited between 1st March and 31st December 2020 were analyzed. Within the framework of the Hamburg City Health Study COVID Program, participants underwent magnetic resonance imaging (MRI) and neuropsychological testing as well as a structured questionnaire for olfactory function. In addition, olfactory function was assessed at an additional timepoint between 15th March and 15th April 2022 including quantitative olfactometric testing with Sniffin’ Sticks.
Exposure SARS-CoV-2 infection confirmed by a positive polymerase chain reaction test (PCR).
Main Outcomes and Measures Primary study outcomes were olfactory dysfunction and the MRI-based measurement of olfactory bulb volume.
Results This study included 233 individuals recovered from mainly mild to moderate SARS-CoV-2 infections (44.2% female, age [years], mean ± SD, 55.79 ± 7.25). Longitudinal assessment demonstrated a declining prevalence of olfactory dysfunction from 67.1% at acute infection, 21.0% at baseline examination (mean ± SD, 8.31 ± 2.77 months post infection) and 17.5% at follow-up (mean ± SD, 21.8 ± 3.61 months post infection). Participants with post-acute olfactory dysfunction had a significantly lower olfactory bulb volume [mm³] at scan-time than normally smelling individuals (mean ± SD, baseline: 40.76 ± 13.08 vs. 46.74 ± 13.66, f = 4.07, p = 0.046; follow-up: 40.45 ± 12.59 vs. 46.55 ± 13.76, f = 4.50, p = 0.036). Olfactory bulb volume predicted olfactometric scores at follow-up (rsp = 0.154, p = 0.025). Performance in neuropsychological testing was not significantly associated with the olfactory bulb volume.
Conclusions Our work demonstrates the association of olfactory dysfunction and olfactory bulb integrity in a sample of individuals recovered from mainly mild to moderate COVID-19. Olfactory bulb volume was demonstrably lower in individuals with sustained olfactory dysfunction and predicted long-term smelling function longitudinally. Collectively, our results highlight olfactory bulb volume as a surrogate marker that may inform diagnosis and guide rehabilitation strategies in COVID-19.
Question Is olfactory dysfunction associated with alterations of the olfactory bulb in individuals who recovered from mild to moderate SARS-CoV-2 infection?
Findings 17.5% of investigated individuals exhibited long term olfactory dysfunction. Olfactory bulb volume was lower in individuals with post-acute olfactory dysfunction and predicted long-term olfactory function.
Meaning Our results demonstrate the link between olfactory function and olfactory bulb integrity after SARS-CoV-2 infection, rendering olfactory bulb volume a promising surrogate marker of long-term smelling outcomes in COVID-19.
Competing Interest Statement
GT has received fees as consultant or lecturer from Acandis, Alexion, Amarin, Bayer, Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and Stryker outside the submitted work. The remaining authors declare no conflicts of interest.
Funding Statement
This work was supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), Project number 454012190 and Sonderforschungsbereich (SFB) 936 - 178316478 - Project C2 (M.P., C.M., G.T., and B.C.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics committee of the Landesaerztekammer Hamburg (State of Hamburg Chamber of Medical Practitioners, PV5131) and conducted complying with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos